G. Bradley Cole
Known title: DirectorCIK: 0001337798
Associated companies
this person other insiders at KNSA
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Castle Biosciences Publishes AD Molecular Testing Study, Opens New Lab. Castle Biosciences highlighted a new study that shows a strong need for molecular testing in atopic dermatitis, supporting its AdvanceAD‑Tx product. The company also announced a new laboratory and office facility in Scottsdale, Arizona, expanding its testing capabilities. These developments reinforce the company's focus on precision diagnostics for skin conditions.
Transaction History
| KNSA | ▼ Sell | Open Market | 3,673 | $299K | 7/29/2026 | View on chart |
| KNSA | ▼ Sell | Gift | 4,500 | $0 | 7/29/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 2,799 | — | 5/29/2026 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 13,667 | — | 5/22/2026 | View on chart |
| CSTL | ▼ Sell | Open Market | 2,655 | $76K | 3/5/2026 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 4,748 | $16K | 3/5/2026 | View on chart |
| CSTL | ▼ Sell | Open Market | 4,748 | $135K | 3/5/2026 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 3,173 | — | 6/5/2025 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 8,673 | — | 5/21/2025 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 4,373 | — | 6/6/2024 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 8,636 | — | 5/25/2024 | View on chart |
| KNSA | ▲ Buy | Option Exercise | 5,000 | — | 6/29/2023 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 3,825 | — | 6/2/2023 | View on chart |
| CSTL | ▲ Buy | Option Exercise | 830 | $0 | 6/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Kiniksa Reports Strong Growth and Accelerating Earnings
Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.
Kiniksa Reports Strong Growth and Accelerating Earnings. Kiniksa Pharmaceuticals has reported earnings that are accelerating, supporting its growth narrative. Analysts note that the company’s performance shows little room for disappointment, reinforcing confidence in its business model. The company’s recent data underscores its position as a solid growth player in the pharmaceutical sector.